AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer
Betsy Goodfellow | April 5, 2024 | News story | Research and Development | AstraZeneca, Imfinzi, Oncology, clinical trial, lung cancer
AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that Imfinzi (durvalumab) had a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients with limited-stage small cell lung cancer (LS-SCLC) who had not progressed following concurrent chemoradiotherapy (cCRT) compared to placebo after cCRT.
The drug’s safety profile remained consistent with previous trials and no new safety signals were observed.
It is anticipated that the data will be presented at an upcoming medical meeting, as well as being shared with the relevant medical authorities.
Imfinzi is already approved in the US, EU, Japan, China and various other countries, for the treatment of extensive-stage SCLC (ES-SCLC) based on results from the CASPIAN phase 3 trial. It is also the only approved immunotherapy and standard-of-care treatment for unresectable, stage 3 non-small cell lung cancer (NSCLC) in patients whose disease has not progressed after CRT based on the PACIFIC phase 3 trial.
Susan Galbraith, executive vice president of Oncology R&D at AstraZeneca, commented: “These exciting results build on the transformative efficacy of Imfinzi in ES-SCLC and demonstrate the potential to bring a curative-intent immunotherapy treatment to this earlier-stage setting of SCLC for the first time. This data, together with the PACIFIC data in unresectable, stage 3 NSCLC, underscore the pioneering role of Imfinzi in the treatment of early lung cancer following chemoradiotherapy.”
Betsy Goodfellow
Related Content
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Tridem Bioscience has enrolled the first patients in a phase Ib clinical trial of TRB-001, …
How will biomarker-led diagnostics reshape respiratory medicine?
By Dr Louise Ryan Murphy, Chronic obstructive pulmonary disease (COPD) is typically diagnosed and assessed …
AstraZeneca’s Trixeo approved in EU for asthma
AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate) has been approved in the European Union as a …
